Steroid Refractory Graft Versus Host Disease
4
1
2
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
25.0%
1 terminated out of 4 trials
0.0%
-86.5% vs benchmark
0%
0 trials in Phase 3/4
0%
1 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Clinical Trials (5)
CK0802 for Treatment of Steroid Refractory Graft vs. Host Disease (GVHD)
Addition of Cord Blood Tissue-Derived Mesenchymal Stromal Cells to Ruxolitinib for the Treatment of Steroid-Refractory Acute Graft Versus Host Disease
Allogeneic CD6 Chimeric Antigen Receptor T Regulatory Cells (CD6-CAR Tregs) for the Treatment of Patients With Chronic Graft Versus Host Disease After Allogeneic Hematopoietic Cell Transplantation
Leflunomide in Treating Patients With Steroid Dependent Chronic Graft Versus Host Disease
Novel BET Inhibitor PLX51107 for Steroid-Refractory Acute GVHD